The 1st subject in the more-than-200-patient CEASE AF study was treated by co-principal investigator Dr. Nicolas Doll of the Sana Heart Center in Stuttgart, Germany, West Chester, Ohio-based AtriCure said.
The trial is designed to compare a combination of surgical ablation of the heart’s outer epicardial layer and catheter ablation of the inner endocardial layer with standard endocardial catheter ablation in patients with enlarged left atria and long-standing, persistent AF over 3 years, the company said. It also aims to evaluate each technique’s economic effects, AtriCure said.
“This is another significant milestone for AtriCure as we continue our advancements in the fight against Afib,” president & CEO Michael Carrel said in prepared remarks. “This important study focuses on a new standard of care for difficult to treat patients.”
“This is the 1st international, prospective, randomized, multi-center study of its kind in these type of patients,” Doll added. “Until the CEASE AF study, studies were mostly single-site.”
“The team approach which involves electrophysiologists and surgeons should have the potential to evolve into an effective treatment strategy for difficult to treat AF patients,” co-principal investigator Dr. Gerhard Hindricks, of Germany’s University of Leipzig Heart Center, said in a prepared statement.